Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis.

COVID-19 SARS-CoV-2 factor analysis of mixed data k-means clustering machine learning neutralizing antibodies principal component analysis random forest

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
18 Jan 2022
Historique:
received: 14 12 2021
revised: 13 01 2022
accepted: 17 01 2022
entrez: 25 2 2022
pubmed: 26 2 2022
medline: 26 2 2022
Statut: epublish

Résumé

Vaccination against SARS-CoV-2 with BNT162b2 mRNA vaccine plays a critical role in COVID-19 prevention. Although BNT162b2 is highly effective against COVID-19, a time-dependent decrease in neutralizing antibodies (NAbs) is observed. The aim of this study was to identify the individual features that may predict NAbs levels after vaccination. Machine learning techniques were applied to data from 302 subjects. Principal component analysis (PCA), factor analysis of mixed data (FAMD), k-means clustering, and random forest were used. PCA and FAMD showed that younger subjects had higher levels of neutralizing antibodies than older subjects. The effect of age is strongest near the vaccination date and appears to decrease with time. Obesity was associated with lower antibody response. Gender had no effect on NAbs at nine months, but there was a modest association at earlier time points. Participants with autoimmune disease had lower inhibitory levels than participants without autoimmune disease. K-Means clustering showed the natural grouping of subjects into five categories in which the characteristics of some individuals predominated. Random forest allowed the characteristics to be ordered by importance. Older age, higher body mass index, and the presence of autoimmune diseases had negative effects on the development of NAbs against SARS-CoV-2, nine months after full vaccination.

Identifiants

pubmed: 35203412
pii: biomedicines10020204
doi: 10.3390/biomedicines10020204
pmc: PMC8869256
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : SYN-ENOSIS (Greece)
ID : SYN-ENOSIS (Greece)
Organisme : IEMBITHEK (Greece)
ID : IEMBITHEK (Greece)

Références

Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Clin Infect Dis. 2021 Dec 6;73(11):2065-2072
pubmed: 33906236
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Am J Hematol. 2022 Jan 1;97(1):119-128
pubmed: 34687462
Lancet Infect Dis. 2021 Sep;21(9):1193
pubmed: 34391506
Expert Rev Anti Infect Ther. 2021 Jul;19(7):877-888
pubmed: 33306423
Cells. 2021 Jul 30;10(8):
pubmed: 34440710
Clin Exp Med. 2021 May;21(2):161-165
pubmed: 33417084
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Nature. 2021 Aug;596(7872):417-422
pubmed: 34192737
Lancet. 2021 Jun 19;397(10292):2331-2333
pubmed: 34090624
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Vaccines (Basel). 2021 Oct 03;9(10):
pubmed: 34696233
Cell. 2018 Jun 14;173(7):1581-1592
pubmed: 29887378
Obes Rev. 2021 Oct;22(10):e13313
pubmed: 34269511
Am J Hematol. 2021 Jul 1;96(7):E257-E259
pubmed: 33837984
Ann Rheum Dis. 2022 Mar;81(3):422-432
pubmed: 34876462
Nat Commun. 2021 Jun 28;12(1):3991
pubmed: 34183681
Lancet Respir Med. 2021 Nov;9(11):e104-e105
pubmed: 34687656
Blood Adv. 2021 Nov 9;5(21):4398-4405
pubmed: 34529762
Clin Exp Med. 2021 Jul 20;:
pubmed: 34283338
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
J Infect. 2021 Jul;83(1):1-16
pubmed: 33992686
Hemasphere. 2021 Dec 17;6(1):e677
pubmed: 34938959
Life (Basel). 2021 Oct 12;11(10):
pubmed: 34685448
Eur J Clin Microbiol Infect Dis. 2021 May;40(5):905-919
pubmed: 33389262
IEEE Rev Biomed Eng. 2021;14:116-126
pubmed: 32746368
Lancet Reg Health Eur. 2021 Nov;10:100208
pubmed: 34514454
Eur J Intern Med. 2021 Jul;89:87-96
pubmed: 34053848
Am J Hematol. 2022 Jan 1;97(1):E3-E7
pubmed: 34674297
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Ann Oncol. 2022 Feb;33(2):158-168
pubmed: 34718117
Clin Exp Med. 2020 Nov;20(4):493-506
pubmed: 32720223
Cancers (Basel). 2021 Sep 06;13(17):
pubmed: 34503290
Blood Cancer J. 2021 Aug 2;11(8):138
pubmed: 34341335

Auteurs

Dimitris Papadopoulos (D)

Section of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece.

Ioannis Ntanasis-Stathopoulos (I)

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Maria Gavriatopoulou (M)

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Zoi Evangelakou (Z)

Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 15784 Athens, Greece.

Panagiotis Malandrakis (P)

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Maria S Manola (MS)

Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 15784 Athens, Greece.

Despoina D Gianniou (DD)

Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 15784 Athens, Greece.

Efstathios Kastritis (E)

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Ioannis P Trougakos (IP)

Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 15784 Athens, Greece.

Meletios A Dimopoulos (MA)

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Vangelis Karalis (V)

Section of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece.

Evangelos Terpos (E)

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Classifications MeSH